H.C. Wainwright Reiterates Their Buy Rating on Spero Therapeutics (SPRO)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Spero Therapeutics (SPROResearch Report) today and set a price target of $10.00. The company’s shares closed last Thursday at $0.81, close to its 52-week low of $0.73.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -37.3% and a 19.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, Oramed Pharmaceuticals, and Oncternal Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Spero Therapeutics with a $4.75 average price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $19.87 and a one-year low of $0.73. Currently, Spero Therapeutics has an average volume of 758K.

Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SPRO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Read More on SPRO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed